Previous 10 | Next 10 |
2023-05-10 16:38:30 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q1 Non-GAAP EPS of $0.41 beats by $0.10 . Revenue of $85.4M (+98.2% Y/Y) beats by $3.78M . Cash and equivalents were $148.2 Million as of March 31, 2023. Affirms Full Year Tot...
Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms F...
Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announce...
CORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today...
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare disea...
2023-04-19 07:51:25 ET Summary The extent to which FIRDAPSE in the treatment of LEMS can support ongoing growth is a big question mark for Catalyst shareholders. The FYCOMPA acquisition comes with more big question marks. Although enjoying comfortable liquidity, Catalyst will ...
2023-04-18 12:00:51 ET Summary Catalyst Pharmaceuticals, Inc. filed a lawsuit against Teva Pharmaceutical Industries Limited's ANDA. At the heart of the situation is a patent that should never have been granted. While courts have not addressed this, instead focusing on orphan ...
2023-04-17 15:42:50 ET Summary Catalyst Pharmaceuticals, Inc. appears to be set up nicely for earnings and revenue growth with a possible expansion of its valuation ratios. Downside appears to be limited, as Catalyst Pharmaceuticals is currently valued in line with its profitable ...
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.49% on the day to $17.69. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people w...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...